Frequency and prognostic impact of antibodies to aquaporin-4 in patients with optic neuritis
Background - Antibodies to aquaporin-4 (AQP4-Ab) are found in 60-80% of patients with neuromyelitis optica (NMO), a severely disabling inflammatory CNS disorder of putative autoimmune aetiology, which predominantly affects the optic nerves and spinal cord. - Objective - To assess the frequency of AQ...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
[15 November 2010]
|
| In: |
Journal of the neurological sciences
Year: 2010, Volume: 298, Issue: 1/2, Pages: 158-162 |
| ISSN: | 1878-5883 |
| DOI: | 10.1016/j.jns.2010.07.011 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.jns.2010.07.011 Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S0022510X10003345 
|
| Author Notes: | Sven Jarius, Jette Frederikson, Patrick Waters, Friedemann Paul, Gulsen Akman-Demir, Romain Marignier, Diego Franciotta, Klemens Ruprecht, Bettina Kuenz, Paulus Rommer, Wolfgang Kristoferitsch, Brigitte Wildemann, Angela Vincent |
| Summary: | Background - Antibodies to aquaporin-4 (AQP4-Ab) are found in 60-80% of patients with neuromyelitis optica (NMO), a severely disabling inflammatory CNS disorder of putative autoimmune aetiology, which predominantly affects the optic nerves and spinal cord. - Objective - To assess the frequency of AQP4-Ab in patients with optic neuritis (ON), and to investigate the prognostic implications of AQP4-Ab seropositivity in such patients. - Patients and methods - AQP4-Ab serum levels were determined in 224 individuals from Austria, Denmark, France, Germany, Italy, and Turkey using a newly developed fluorescence immunoprecipitation assay employing recombinant human AQP4. - Results - AQP4-Ab were detectable in 8/139 (5.8%) patients with acute monosymptomatic optic neuritis (AMON) and in 10/17 (58.8%) patients with established NMO and a last relapse of acute ON (NMO/ON), but not in 32 patients with multiple sclerosis or in 36 healthy controls. At last examination, 4/8 (50%) seropositive AMON patients had met the criteria for NMO but 0/128 seronegative AMON patients. Disease severity differed significantly between seropositive and seronegative AMON. Complete bilateral or unilateral blindness occurred in six AQP4-Ab positive patients, but only in one AQP4-Ab negative patient. AQP4-Ab levels did not vary between seropositive AMON and NMO/ON and did not correlate with disease severity. Female gender, a relapsing course, and concomitant autoimmunity were associated with AQP4-Ab seropositive status and risk of developing NMO. - Conclusion - AQP4-Ab is relatively rare among patients with AMON, but if present it predicts a high rate of conversion to NMO within one year. |
|---|---|
| Item Description: | Gesehen am 26.07.2023 |
| Physical Description: | Online Resource |
| ISSN: | 1878-5883 |
| DOI: | 10.1016/j.jns.2010.07.011 |